

Selective estrogen receptor degraders - Pipeline Insight, 2022

<https://marketpublishers.com/r/S06A9D5388C0EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: S06A9D5388C0EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Selective Estrogen Receptor Degradators - Pipeline Insight, 2022" report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Selective Estrogen Receptor Degradators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Selective Estrogen Receptor Degradators Understanding

Selective Estrogen Receptor Degradators: Overview

Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER positive breast cancers. Selective modulation of ER has been a therapeutic target for this specific type of breast cancer.

Function - Estrogens, a class of steroid hormones, regulate the growth, development, and physiology of the human reproductive system. Estrogens also involve in the neuroendocrine, skeletal, adipogenesis, and cardiovascular systems. Estrogen signaling pathways are selectively stimulated or inhibited depending on a balance

between the activities of estrogen receptor (ER) ? or ER? in target organs. ERs belong to the steroid hormone superfamily of nuclear receptors, which act as transcription factors after binding to estrogen. The gene expression regulation by ERs is to modulate biological activities, such as reproductive organ development, bone modeling, cardiovascular system functioning, metabolism, and behavior in both females and males.

Selective Estrogen Receptor Degraders- A selective estrogen receptor degrader or downregulator (SERD) is a type of drug which binds to the estrogen receptor (ER) and, in the process of doing so, causes the ER to be degraded and thus downregulated. They are used to treat estrogen receptor-sensitive or progesterone receptor-sensitive breast cancer, along with older classes of drugs like selective estrogen receptor modulators (SERMs) and aromatase inhibitors.

Selective Estrogen Receptor Degraders Emerging Drugs Chapters

This segment of the Selective Estrogen Receptor Degraders report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Selective Estrogen Receptor Degraders Emerging Drugs

Elacestrant: Radius Health

Elacestrant is a selective estrogen receptor degrader (SERD), out-licensed to Menarini Group, which is being evaluated for potential use as a once daily oral treatment in patients with ER+/ HER2- advanced breast cancer. Studies completed to date indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+/HER2- advanced/metastatic breast cancer patients.

Giredestrant: Genentech

Giredestrant (formerly GDC 9545) is an oral selective estrogen receptor degrader, being

developed Genentech, for the treatment of breast cancer. The drug is currently in phase 3 of clinical development.

Further product details are provided in the report.....

Selective Estrogen Receptor Degraders: Therapeutic Assessment

This segment of the report provides insights about the different Selective Estrogen Receptor Degraders drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Selective Estrogen Receptor Degraders

There are approx. 14+ key companies which are developing the Selective Estrogen Receptor Degraders. The companies which have their Selective Estrogen Receptor Degraders drug candidates in the most advanced stage, i.e. phase III include, Radius Health.

Phases

DelveInsight's report covers around 14+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Selective Estrogen Receptor Degraders pipeline report provides the therapeutic

assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Selective Estrogen Receptor Degraders: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Selective Estrogen Receptor Degraders therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Selective Estrogen Receptor Degraders drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Selective Estrogen Receptor Degraders R&D. The therapies under development are focused on novel approaches for Selective Estrogen Receptor Degraders.

Selective Estrogen Receptor Degraders Report Insights

Selective Estrogen Receptor Degraders Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Selective Estrogen Receptor Degraders Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Selective Estrogen Receptor Degraders drugs?

How many Selective Estrogen Receptor Degraders drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Selective Estrogen Receptor Degraders?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Selective Estrogen Receptor Degraders therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Selective Estrogen Receptor Degraders and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Radius Health

Genentech

Olema Pharmaceuticals

Eli Lilly and Company

Aragon Pharmaceuticals

Novartis

Sanofi

Sun Pharma Advanced Research Company

G1 Therapeutics

Shandong Luoxin Pharmaceutical

AstraZeneca

Zeno Alpha

InventisBio

Atossa Therapeutics

Evestra

Key Products

Elacestrant

Giredestrant

OP 1250

LY 3484356

RG 6047

LSZ 102

Amcenestrant

SCO 120

Rintodestrant

LX 039

AZD 9833

ZN c5

D 0502

Fulvestrant intraductal

EC 372

Contents

Introduction

Executive Summary

Selective Estrogen Receptor Degraders: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Selective Estrogen Receptor Degraders – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Selective Estrogen Receptor Degraders companies' collaborations, Licensing,
Acquisition -Deal Value Trends

Selective Estrogen Receptor Degraders Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Elacestrant: Radius Health

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

LY 3484356: Eli Lilly and Company

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

EC 372: Evestra

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

Selective Estrogen Receptor Degradable Key Companies

Selective Estrogen Receptor Degradable Key Products

Selective Estrogen Receptor Degradable- Unmet Needs

Selective Estrogen Receptor Degradable- Market Drivers and Barriers

Selective Estrogen Receptor Degradable- Future Perspectives and Conclusion

Selective Estrogen Receptor Degradable Analyst Views

Selective Estrogen Receptor Degradable Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Selective Estrogen Receptor Degradors

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Selective Estrogen Receptor Degraders

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Selective estrogen receptor degraders - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/S06A9D5388C0EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S06A9D5388C0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970